These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 10158460)

  • 1. Potential savings from generic prescribing and generic substitution in South Africa.
    Karim SS; Pillai G; Ziqubu-Page TT; Cassimjee MH; Morar MS
    Health Policy Plan; 1996 Jun; 11(2):198-205. PubMed ID: 10158460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fundholding and indicative prescribing schemes on general practitioners' prescribing costs.
    Bradlow J; Coulter A
    BMJ; 1993 Nov; 307(6913):1186-9. PubMed ID: 8251847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic drug prescriptions following hospital discharge: a prospective study in France.
    Chu C; Rudant E; Bonvalet M; Agostini H; Cavalié P; Bonhomme-Faivre L; Frenkiel J; Taillandier J; Boissonnas A; Vittecoq D; Wyplosz B
    Eur J Intern Med; 2011 Oct; 22(5):e45-9. PubMed ID: 21925042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data.
    Goldacre B; Reynolds C; Powell-Smith A; Walker AJ; Yates TA; Croker R; Smeeth L
    BMJ Open; 2019 Feb; 9(2):e026886. PubMed ID: 30813120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case study of the effects of office-based generic drug sampling on antibiotic drug costs and first-line antibiotic prescribing ratios.
    Conklin MH; Culley EJ; O'Donnell J
    J Manag Care Pharm; 2009; 15(1):55-61. PubMed ID: 19125550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
    Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.
    Ann Intern Med; 2005 Jun; 142(11):I30. PubMed ID: 15941691
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience of a medicines reference-pricing model.
    Rothberg AD; Blignault J; Serfontein CB; Valodia B; Eekhout S; Pels LM
    S Afr Med J; 2004 Mar; 94(3):183-8. PubMed ID: 15098277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
    Counterweight Project Team
    J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New mechanism to identify cost savings in English NHS prescribing: minimising 'price per unit', a cross-sectional study.
    Croker R; Walker AJ; Bacon S; Curtis HJ; French L; Goldacre B
    BMJ Open; 2018 Feb; 8(2):e019643. PubMed ID: 29439078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measures to reduce costs for prescriptions in Vienna--preliminary analysis].
    Tönies H
    Wien Med Wochenschr; 2009; 159(7-8):196-201. PubMed ID: 19412694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.